Introduction
Many antineoplastic agents (but not all) are known to have also antiviral activity. Quite recently, the value of anticancer agents for the development of anti-HIV drugs has been heavily emphasized (Sadaie et al., 2004) , and it has been proposed that they could suppress HIV strains that are resistant to 'traditional' inhibitors of viral enzymes, decrease proviral burden in vivo, or reduce reservoirs of infection via killing infected cells, and thus might be an effective adjunct therapy or perhaps result in a cure (Sadaie et al., 2004) . The present author and Lumme have shown (Elo and Lumme, 1985) that trans-bis(salicylaldoximato)copper(II) (CuSAO 2 ; R = RЈ = H; see Fig. 1 ) is a powerful antitumour agent in vivo, being capable of drastically increasing the life span of mice bearing Ehrlich ascites carcinoma. In many cases, the compound has even a curative effect. This compound as well as many of its congeners, most notably the 4-hydroxylated analogue trans-bis(resorcylaldoximato)copper(II) (CuRES 2 ; R = H, RЈ = OH; see Fig. 1 ), also have potent antiproliferative activity against tumour cells in vitro [Elo and Lumme, 1986, 1987 (for further references on the properties of these agents, see Elo and Lumme, 1987) ]. Thus, also salicylaldoximato-type chelates are worth screening for antiviral properties, especially as they are also known to have immunomodulating properties (Elo and Lumme, 1986 1987; Elo, 1987; unpublished results) . In this paper, I report the screening of two compounds of this family, namely CuRES 2 and trans-bis (2,3,4-trihydroxybenzaldoximato) copper(II) (CuTRI 2 ; R = RЈ = OH; see Fig. 1 ), against the cytopathic effects of the human immunodeficiency virus (HIV).
Experimental
CuTRI 2 was tested against the cytopathic effects of HIV according to the standard protocols of the U. S. National Cancer Institute. The assay employed basically involves the killing of T4 lymphocytes by HIV. In brief, the procedure consisted of the following steps: T4 lymphocytes (CEM-V and CEM-Z cell lines) were exposed to HIV at a virus to cell ratio approx. 0.05, and plated along with noninfected control cells in 96-well microtiter plates. CuTRI 2 was then diluted to 1:200 in the cell culture medium. Further dilutions (half-log 10 ) were prepared before adding to an equal volume of medium containing either infected or noninfected cells. Cultures were incubated at 37 ∞C in a 5% carbon dioxide atmosphere for 6 or 7 d. The tetrazolium salt XTT {i.e., 2,3-bis(2-methoxy-4-nitro-5-sulphenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide, inner salt, sodium salt}, an agent whose metabolic reduction gives a coloured formazan compound (Scudiero et al., 1988) , was added to all wells, and the cultures were incubated to allow formazan colour development by viable cells. Individual wells were analyzed spectrophotometrically to quantitate the formazan production, and in addition were viewed microscopically for detection of viable cells. Data were reviewed in comparison with other tests done at the same time.
The tests were also compared with a positive [zidovudine (azidothymidine, 'AZT')-treated] control done at the same time under identical conditions.
CuRES 2 was tested essentially similarly. In the case of CuRES 2 , the cell line used was MT-2 (a human leukemia). CuRES 2 was synthesized according to a modification of the method of Mu- kherjee (1955) . The experimental details will be published elsewhere, as will also the synthesis of CuTRI 2 .
Results and Discussion
The results obtained are shown in Tables I and  II. As it is evident from the Tables, neither CuRES 2 nor CuTRI 2 (Fig. 1) had any detectable activity against the cytopathic effects of HIV in cultures of MT-2 cells and CEM cells, respectively. Neither agent increased the viability of HIV-infected cells in the concentration range employed. Instead, the highest tested concentrations of both vations of the present author and his coworkers that indicate that CuSAO 2 and CuRES 2 have strong cytotoxic effects in vitro against a variety of human and murine tumour cells and that those effects are essentially irreversible and occur in hours or even within one hour or less. As the ability of copper(II) chelates of salicylaldoximates to inhibit the proliferation of mammalian cells is concerned, the present results are clearly in line with previous ones obtained under a variety of different conditions (Elo and Lumme, 1986, 1987; Elo, 2004; unpublished observations) . Thus, both compounds tested were potent antiproliferative agents also in the present test system, in which the experimental details (e.g., incubation time, cell lines) were different from those used in most studies previously reported. Thus, also the present results clearly suggest that copper salicylaldoximates have a very broad spectrum of activity.
